Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3807.96% is 545% below its 4-year average of -590.32%, near the low end of its 4-year range (-3807.96%–52.33%).
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 52.33%.
EBITDA MARGIN
-3807.96%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
-811.52%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-369.24%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Werewolf Therapeutics, Inc.
Market Cap
$44.98M
EBITDA Margin
-3807.96%
TTM Avg
N/A
3Y Avg
-811.52%
5Y Avg
N/A
Market Cap
$44.84M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$44.29M
EBITDA Margin
-376.33%
TTM Avg
-387.64%
3Y Avg
-608.18%
5Y Avg
-1395.53%
Market Cap
$44.31M
EBITDA Margin
-148.02%
TTM Avg
-167.05%
3Y Avg
-193.51%
5Y Avg
-252.90%
Market Cap
$42.86M
EBITDA Margin
-89.16%
TTM Avg
-101.97%
3Y Avg
-124.94%
5Y Avg
-147.77%
Market Cap
$47.98M
EBITDA Margin
22.86%
TTM Avg
-25.83%
3Y Avg
-102.29%
5Y Avg
-102.29%
Market Cap
$48.76M
EBITDA Margin
-30422.22%
TTM Avg
-16673.71%
3Y Avg
-8702.25%
5Y Avg
-6477.94%
Market Cap
$49.15M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $44.98M | -3807.96% | N/A | -811.52% | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $44.84M | -0.99% | 4.72% | -25.09% | -32.37% |
| Nano-X Imaging Ltd. (NNOX)vs › | $44.29M | -376.33% | -387.64% | -608.18% | -1395.53% |
| DarioHealth Corp. (DRIO)vs › | $44.31M | -148.02% | -167.05% | -193.51% | -252.90% |
| CVRx, Inc. (CVRX)vs › | $42.86M | -89.16% | -101.97% | -124.94% | -147.77% |
| Lite Strategy, Inc. (LITS)vs › | $47.98M | 22.86% | -25.83% | -102.29% | -102.29% |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.71M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $48.76M | -30422.22% | -16673.71% | -8702.25% | -6477.94% |
| Apollomics, Inc. (APLM)vs › | $49.15M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Clene Inc. (CLNN)vs › | $49.68M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
Gross Margin
0.0%
EBITDA Margin
-3808.0%
Operating Margin
0.0%
Net Margin
-164.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 52.33% |
| 2024-06-30 | -1619.07% |
| 2024-03-31 | -2250.40% |
| 2023-12-31 | -832.91% |
| 2023-09-30 | -149.33% |
| 2023-06-30 | -69.71% |
| 2023-03-31 | -264.29% |
| 2022-12-31 | -175.23% |
| 2022-09-30 | -238.05% |
| 2022-06-30 | -356.49% |
